Clin Assoc Prof Tham Chee Kian

MBBS (S’pore), MMed (Internal Medicine), MRCP (UK)

Deputy Chairman & Senior Consultant

National Cancer Centre Singapore National Cancer Centre Singapore

Specialty: Medical Oncology

Clinical Interests

Gastrointestinal, Neuro-Oncology

Clinical Appointments

Deputy Chairman & Senior Consultant

Division of Medical Oncology

Academic Appointments

Clinical Associate Professor

About

Dr Tham Chee Kian is the Deputy Chairman and Senior Consultant at the Division of Medical Oncology at the National Cancer Centre Singapore (NCCS). His subspecialty interest is in neuro-oncology and gastrointestinal oncology. He also holds an academic appointment as Clinical Associate Professor with the Duke-NUS Medical School.

Education and Training

  • Master of Medicine (Internal Medicine), National University of Singapore 
  • Bachelor of Medicine and Surgery (MBBS), National University of Singapore

Professional Appointments and Committee Memberships

  • Chairman, Chapter of Medical Oncology, Fellowship of the Academy of Medicine, Singapore (FAMS), 2025 - 
  • Member, Clinical Review Committee, Hospice Care Association (HCA), Singapore, 2022 -

Awards

  • SingHealth Residency, Program Director Award, 2023 
  • SingHealth Medicine Academic Program (ACP), Education Leader Award, 2021 
  • SingHealth GCEO Excellence Awards, Outstanding Educator Award, 2019 
  • SingHealth Quality Service Silver Award 2010, 2011, 2018, 2021, 2025

Research Trials

  • ONC201-108 - ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Fol-lowing Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study, Site Principal Investigator, 2024 
  • A phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adult patients with advanced solid tumors (CBLZ945X2101). Site Principal Investigator, 2020 
  • ABT-414 alone or ABT-414 plus temozolomide vs. lomustine or temozolomide for recurrent glio-blastoma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC protocol 1410-BTG), Site Principal Investigator, 2016 
  • A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1). Site Principal Investigator, 2016

Publications

  • Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an interna-tional, multicentre, phase 3, randomized, double-blind, placebo-controlled trial. J Chia, E Segeov, Y Deng, GF Ho, W Wang, S Han, A Sharma, K Ding, G Chen, M Jeffrey, CK Tham, JB Ahn, L Nott, R Ziel-inski, T Chao, T Hagen, P Wei, F Day, S Mehta, T Yau, J Peng, T Hayes, Y Li, M Gandhi, E FooN Rah-man, P Rothwell, R Ali, J Simes, HC Toh. Lancet Gastroenterol Hepatol. 2025 
  • Tumour growth rate predicts overall survival in patients with recurrent WHO grade 4 glioma. Pang JHW, Saffari SE, Lee GR, Yu W, Lim TCC, Lim KC, Lee CC, Koh WY, Chia WTD, Chua KLM, Tham CK, Low SYY, Ng WH Low CYD, Lin XL. BMC Med Imaging, May 2024; 24(1):125. 
  • Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellu-lar carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. David Tai Kelvin Loke, Apoorva Gogna, Neslihan Arife Kaya, Sze Huey Tan, Tiffany Hennedige, David Ng, Farah Irani Joycelyn Lee, Jia Qi Lim, Chow Wei Too, Matthew C H Ng, Chee Kian Tham, Justina Lam, Si Lin Koo, Hui Shan Chong, George Boon-Bee Goh, Hian Liang Huang, Nanda Venkatanarasimha, Richard Lo, Pierce K H Chow, Brian K P Goh, Alexander Chung, Han Chong Toh, Prof Choon Hua Thng, Prof Tony K H Lim, Joe Yeong, Weiwei Zhai, Chung Yip Chan, Su Pin Choo. The Lancet Gastroenterology & Hepatology Oct 23, 2021. 
  • Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recur-rence and survival of patients with colorectal cancer. Tham CK, Chew M, Soong R, Lim J, Ang M, Tang C, Zhao Y, Ong SY, Liu Y. Cancer. 2014 Oct 15;120(20):3131-41. 
  • Combined temozolomide and radiation as an initial treatment for anaplastic glioma. Tham CK, See SJ, Tan SH, Lim KH, Ng WH, Thomas J, Chong DQ, Chua ET. Asia Pac J Clin Oncol. 2012 Dec 21.